ACHV - Achieve Life's cytisinicline shows efficacy in smoking cessation treatment

Achieve Life Sciences (ACHV) announces results from Phase 2b ORCA-1 trial in scientific journal Nicotine and Tobacco Research. ORCA-1 evaluated the efficacy and safety of cytisinicline across various dosing schedules in 254 smokers.Subjects treated with cytisinicline had statistically significantly higher (p<0.001) end of treatment abstinence rates compared to those treated with placebo.Participants in the 3.0 mg cytisinicline 3 times daily ((TID)) arm, were 5-times more likely to quit smoking than those in the placebo arm (OR of 5.04, 95% CI: 1.42, 22.32, p<0.001). Cytisinicline was well-tolerated with no serious or severe adverse events (AEs) reported.Adherence to study treatment was greater than 94% across all treatment arms and 98% in the 3.0 mg TID arm, specifically.

For further details see:

Achieve Life's cytisinicline shows efficacy in smoking cessation treatment